FY2025 Earnings Forecast for WVE Issued By Cantor Fitzgerald

Key Points

• Cantor Fitzgerald revised its FY2025 earnings estimate for WAVE Life Sciences Ltd. to ($1.09) per share, slightly down from the previous estimate of ($1.07), while maintaining an "Overweight" rating and a $10.00 target price.
• Multiple analysts have issued ratings for WAVE Life Sciences, with a consensus rating of "Moderate Buy" and an average price target of $20.36, amidst expectations of earnings of ($1.14) per share for the current year.
• WAVE Life Sciences recently reported a missing earnings estimate of ($0.31) per share for the last quarter, alongside revenue of $8.70 million, which fell short of the consensus estimate of $11.52 million.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for shares of WAVE Life Sciences in a research report issued on Thursday, July 31st. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will post earnings of ($1.09) per share for the year, down from their previous estimate of ($1.07). Cantor Fitzgerald currently has a "Overweight" rating and a $10.00 target price on the stock. The consensus estimate for WAVE Life Sciences' current full-year earnings is ($1.14) per share. Cantor Fitzgerald also issued estimates for WAVE Life Sciences' FY2026 earnings at ($1.29) EPS.

Several other equities research analysts also recently weighed in on the stock. Oppenheimer started coverage on shares of WAVE Life Sciences in a research report on Monday, July 28th. They issued an "outperform" rating and a $24.00 target price for the company. Raymond James Financial started coverage on shares of WAVE Life Sciences in a research report on Wednesday, June 11th. They set an "outperform" rating and a $14.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and set a $18.00 price objective on shares of WAVE Life Sciences in a research report on Monday, June 23rd. Wells Fargo & Company lowered their price objective on shares of WAVE Life Sciences from $24.00 to $21.00 and set an "overweight" rating for the company in a research report on Thursday. Finally, Citigroup started coverage on shares of WAVE Life Sciences in a research report on Wednesday, July 16th. They set a "buy" rating and a $16.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $20.36.

WAVE Life Sciences Stock Performance

WVE opened at $8.63 on Monday. The company has a 50-day moving average of $7.22 and a 200-day moving average of $8.27. The company has a market capitalization of $1.37 billion, a P/E ratio of -9.59 and a beta of -0.95. WAVE Life Sciences has a 1-year low of $5.04 and a 1-year high of $16.74.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $11.52 million.

Institutional Trading of WAVE Life Sciences

A number of institutional investors have recently made changes to their positions in WVE. GF Fund Management CO. LTD. acquired a new stake in shares of WAVE Life Sciences in the 4th quarter worth approximately $40,000. Quarry LP acquired a new stake in WAVE Life Sciences during the fourth quarter valued at approximately $62,000. Knott David M Jr acquired a new stake in WAVE Life Sciences during the first quarter valued at approximately $81,000. Ascent Group LLC acquired a new stake in WAVE Life Sciences during the first quarter valued at approximately $83,000. Finally, Chicago Partners Investment Group LLC acquired a new stake in WAVE Life Sciences during the first quarter valued at approximately $103,000. 89.73% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at WAVE Life Sciences

In other WAVE Life Sciences news, Director Gregory L. Verdine sold 30,000 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $6.95, for a total transaction of $208,500.00. Following the completion of the transaction, the director directly owned 282,517 shares of the company's stock, valued at $1,963,493.15. The trade was a 9.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 23.98% of the stock is owned by insiders.

WAVE Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.